Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.35 |
| ▸ | MMP3 | P08254 | 6/20 | 0.35 |
| ▸ | MMP1 | P03956 | 4/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4633169 | 1.00 | MME (0.42) | MMESLC6A3MMP3MMP1MMP2 | |
| SCHEMBL4635104 | 0.89 | MME (0.41) | MMEMMP3MMP1MMP2MMP9 | |
| SCHEMBL15140380 | 0.80 | SLC6A3 (0.38) | MMESLC6A3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL4635116 | 0.79 | MME (0.40) | MMESLC6A3MMP3MMP1MMP2 | |
| SCHEMBL23911882 | 0.77 | CCNA2 (0.35) | SLC6A3MEN1KMT2A | |
| SCHEMBL7385209 | 0.76 | CCNA2 (0.34) | SLC6A3MEN1KMT2AHTT | |
| SCHEMBL31051154 | 0.75 | TSHR (0.38) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30940157 | 0.74 | CCNA2 (0.38) | SLC6A3SMN1; SMN2MEN1KMT2A | |
| SCHEMBL30564337 | 0.72 | CTSK (0.36) | KMT2A | |
| SCHEMBL20764812 | 0.72 | ALDH1A1 (0.39) | MEN1KMT2ACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931624-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | Serentis Limited (GB) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007025999-A1 | USE OF AN AUREOLYSIN INHIBITOR FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS CHARACTERISED BY COLONISATION WITH STAPHYLOCOCCUS AUREUS | SERENTIS LIMITED (GB) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | SERENTIS LIMITED (GB) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049518-A1 | Novel method of treatment of inflammatory skin conditions | MMP8, CUTA, MMP1 | MME 540/4885SLC6A3 4884/4885MMP3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.